Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
|Active Ingredient:||Clozapine 50mg/mL|
|Dosage Form:||Oral suspension|
|New Zealand Sponsor:||Douglas Pharmaceuticals Limited|
|Manufacturer:||Pharmaceutics International Inc, Maryland, United States of America|
Note: This consent is given subject to the following conditions:
- The medicine may only be prescribed by:
- A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist).
- A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist.
- A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team.
Note: This renewed consent is valid for two years from 14 May 2022.
Dated this 13th day of May 2022.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).